Implementation issues affecting patient access to Medicare covered pharmaceuticals and biologics, including reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements. Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including advocacy related to the Most Favored Nation and related demonstration initiatives.
340B Program issues and patient access to pharmaceuticals. Legislative issues associated with patient access to treatment, including: the CMMI Most Favored Nation and related demonstration initiatives; and step therapy. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains. Enhanced FDA reporting and risk mitigation plans for certain medicines. Incentives for antimicrobial and antiviral research, medical countermeasures, and novel product development.